TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

TG THERAPEUTICS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$53.30−0.67 (-1.24%)

Close on Oct 19, 2026

Community

Notes and questions about Tg Therapeutics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Tg Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-50 reverse split on Jul 14, 2011
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TGTX.

Revenue growth76.1% · median 38.5%

Gross margin82.4% · median 83.5%

Operating margin17.1% · median -70.8%

Net margin55.2% · median -76.9%

Advertisement
300 × 250